Status:

COMPLETED

A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks

Lead Sponsor:

Children's Hospital Medical Center, Cincinnati

Collaborating Sponsors:

National Center for Research Resources (NCRR)

Conditions:

Sleep Apnea

Sleep Disordered Breathing

Eligibility:

All Genders

18-60 years

Phase:

PHASE1

PHASE2

Brief Summary

This is an open label, controlled study. The investigators are studying if the FDA approved diabetes medicine liraglutide (Victoza®) can improve sleep apnea in adults. This study is testing liragluti...

Detailed Description

This is a pilot study aimed at measuring the change in obstructive apnea/hypopnea index in non-diabetic patients being treated for the first time with the glucagon-like peptide-1 (GLP-1) agonist, Lira...

Eligibility Criteria

Inclusion

  • Age 18-60 years
  • Diagnosis of severe obstructive sleep apnea (OSA) AHI ≥ 8 /hour of sleep
  • Ability and willingness to comply with all protocol procedures e.g. correct handling of trial product, compliance to visit schedule
  • BMI of ≥ 27
  • For Cohort 1: If female of childbearing capacity, willing to use acceptable birth control during use of study drug

Exclusion

  • A major medical condition such as renal or hepatic failure
  • Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 inhibitors or insulin within the last 3 months prior to screening
  • Diagnosis of type 1 or type 2 diabetes per judgment of the investigator
  • BMI \< 27
  • History of glycosylated hemoglobin (HbA1c) equal to or above 6.5%
  • Significant craniofacial abnormalities that may cause OSA
  • Respiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of the investigator
  • Use of central stimulants, hypnotics, mirtazepine, opioids, trazodone or drugs in the incretin family within the previous 3 months prior to screening
  • Previous surgical treatment for obesity
  • Familial or personal history of Multiple Endocrine Neoplasia type 2 or familial Medullary Thyroid Carcinoma
  • Personal or immediate family history of thyroid cancer
  • History of chronic pancreatitis or idiopathic acute pancreatitis
  • History of Major Depressive Disorder or suicide attempts
  • Systolic blood pressure equal to or above 160 mmHg and/or diastolic blood pressure equal to or above 100 mmHg
  • History of alcoholism
  • Pregnancy or breastfeeding

Key Trial Info

Start Date :

April 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2015

Estimated Enrollment :

34 Patients enrolled

Trial Details

Trial ID

NCT01832532

Start Date

April 1 2013

End Date

December 1 2015

Last Update

October 20 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229